Immutep enters into clinical trial collaboration agreement with Cytlimic

Immutep Limited announced that it has entered into a clinical trial collaboration agreement, a supply agreement and a service agreement with CYTLIMIC Inc. for its lead product candidate eftilagimod alpha as part of a cancer vaccine. The agreements enable the two parties to collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine containing CYTLIMIC’s innovative cancer peptide vaccine, called CYT001. The trials will be conducted by and are under the control of CYTLIMIC who will fully fund all development costs. Under the collaboration agreement, Immutep will receive an upfront payment of $500,000 and is eligible to receive up to $4.5M in milestone payments upon the achievement of milestones by CYTLIMIC. https://thefly.com/landingPageNews.php?id=2844487